1

Humoral and Cellular Immunogenicity and Safety of 3 Doses of CoronaVac and 1 BNT162b2 in Young Children and Adolescents with Kidney Diseases 2

- 3
- Daniel Leung,^{1,*} Eugene Yu-hin Chan,^{2,*} Xiaofeng Mu,^{1,*} Jaime S Rosa Duque,^{1,*} Samuel 4
- 5
- 6
- MS Cheng,^{3,*} Fanny Tsz-wai Ho,² Pak-chiu Tong,² Wai-ming Lai,² Matthew HL Lee,⁴ Stella Chim,⁴ Issan YS Tam,¹ Leo CH Tsang,³ Kelvin KH Kwan,³ Yuet Chung,¹ Howard HW Wong,¹ Amos MT Lee,¹ Wing Yan Li,¹ Summer TK Sze,¹ Jennifer HY Lam,¹ Derek HL Lee,¹ Sau Man Chan,¹ Wenwei Tu,^{1,†} Malik Peiris,^{3,5,†} Alison Lap-tak Ma,^{2,†} Yu Lung Lau,^{1,†} 7
- 8
- ¹ Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong 9 Kong, China 10
- ² Pediatric Nephrology Centre, Department of Pediatrics and Adolescent Medicine, Hong 11
- 12 Kong Children's Hospital, Hong Kong, China
- ³ School of Public Health, The University of Hong Kong, Hong Kong, China 13
- ⁴ Department of Pediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong, 14 China 15
- ⁵ Centre for Immunology & Infection C2i, Hong Kong, China 16
- 17
- 18 *, denotes co-first authors who contributed equally
- [†], denotes co-corresponding authors who contributed equally 19
- 20

31

21 Running Title: CoronaVac and BNT162b2 in pediatric kidney patients

22 **Corresponding authors:**

23 Wenwei Lu, MBBS, PhD

- 24 Email: wwtu@hku.hk
- 25 Address: 7/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong.
- 26 Malik Peiris, MBBS, DPhil 27
- Email: malik@hku.hk 28
- Address: Centre for Immunology & Infection, 11/F, Building 17W, Hong Kong 29 30 Science Park, Shatin, Hong Kong.
- Alison Lap-tak Ma, MBBS, FRCPCH(UK) 32
- Email: malta@ha.org.hk 33
- Address: 9/F, Tower B, Hong Kong Children's Hospital, Kowloon Bay, 34
- 35 Hong Kong.
- 36 37 Yu Lung Lau, MBChB, MD(Hons)
- Email: lauylung@hku.hk 38
- Address: 1/F, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong. 39
- 41 Key words: BNT162b2, CoronaVac, COVID-19, kidney diseases, vaccine
- 42 Length: 2912 words (excluding Methods)
- 43 Tables and Figures: 2 and 5
- 44

40

Funding: HKSAR Government COVID19F02, COVID19F10, and COVID19F12. 45

46 SIGNIFICANCE STATEMENT

47 Little is known about the effectiveness of COVID-19 vaccines in children and adolescents 48 with kidney diseases. This paper describes the antibody and T cell responses of 3 doses of 49 CoronaVac or BNT162b2, the top 2 COVID-19 vaccines distributed worldwide, by an 50 accelerated regimen in patients with kidney diseases aged 1-18 years. Antibody and T cell 51 responses were significantly elicited by either vaccine. Neutralization was reduced against Omicron while T cell response was preserved, which likely confer protection against severe 52 53 COVID-19. Rate of severe adverse reactions was low in the study. Results confirm that 54 accelerated 3-dose primary series with CoronaVac and BNT162b2 is safe and immunogenic 55 in young children and adolescents with kidney diseases. 56 57 ABSTRACT 58 Background: Patients with kidney diseases are at risk of severe complications from COVID-59 19, yet little is known about the effectiveness of COVID-19 vaccines in children and 60 adolescents with kidney diseases. 61 Methods: We investigated the immunogenicity and safety of an accelerated, 3-dose primary 62 series of COVID-19 vaccines among 64 pediatric chronic kidney disease patients (mean age 63 12.2; 32 male) with or without immunosuppression, dialysis, or kidney transplant. 64 CoronaVac was given to those aged <5 years, 0.1ml BNT162b2 to those aged 5-11 years, 65 and 0.3ml BNT162b2 to those aged 11-18 years. 66 Results: Antibody responses including S-RBD IgG (90.9-100% seropositive) and surrogate 67 virus neutralization (geometric mean sVNT% level, 78.6-94.0%) were significantly elicited by 68 3 doses of any vaccine. T cell responses were also elicited. Weaker neutralization 69 responses were observed among kidney transplant recipients and non-dialysis children 70 receiving rituximab for glomerular diseases. Neutralization was reduced against Omicron 71 BA.1 compared to wild-type (post-dose 3 sVNT% level; 84% vs 27.2%; p<0.0001). However, 72 T cell response against Omicron BA.1 was preserved, which likely confer protection against

It is made available under a CC-BY-NC-ND 4.0 International license .

- 73 severe COVID-19. Hybrid immunity was observed after vaccination in infected patients, as
- 74 evidenced by higher Omicron BA.1 neutralization response among infected patients
- receiving 2 doses than those uninfected. Generally mild or moderate adverse reactions
- 76 following vaccines were reported.
- 77 Conclusions: Our findings support that an accelerated 3-dose primary series with CoronaVac
- and BNT162b2 is safe and immunogenic in young children and adolescents with kidney
- 79 diseases.
- 80

81 TRIAL REGISTRATION

82 Clinicaltrials.gov NCT04800133

It is made available under a CC-BY-NC-ND 4.0 International license .

83 INTRODUCTION

84	Patients with chronic kidney disease and kidney failure are at risk of severe disease and
85	mortality in the COVID-19 pandemic. ¹ Impaired immune function in children and adolescents
86	with severe kidney diseases predisposes them to infections, ² and vaccination offers
87	protection to this vulnerable population. BNT162b2 is an mRNA vaccine with 90-100%
88	efficacy against symptomatic COVID-19 caused by pre-Omicron variants in healthy children
89	and adolescents aged 5-15 years. ^{3,4} CoronaVac is a whole-virus inactivated vaccine with
90	robust immunogenicity and real-world effectiveness demonstrated in children aged 3-17
91	years. ⁵⁻⁸ In many places, including Hong Kong, immunocompromised children and
92	adolescents are recommended to receive a 3-dose mRNA or inactivated vaccine primary
93	series, due to their clinical vulnerability and suboptimal immunogenicity.9
94	
95	We have previously shown that the antibody responses elicited by 2 doses of BNT162b2
96	were diminished in adolescents with kidney diseases. ¹⁰ However, data pertaining to the
97	immunogenicity and safety of COVID-19 vaccines among the pediatric population remain
98	extremely scarce. ^{11,12} Data concerning the humoral and cellular immunogenicity to 3-dose
99	primary series of COVID-19 vaccines among young children with kidney diseases, as well as
100	immunogenicity against the Omicron variant, are lacking.
101	
102	We initiated a 3-year non-randomized study (NCT04800133) to investigate the use of
103	COVID-19 vaccines in children and adolescents in Hong Kong. In the present interim
104	analysis, we recruited younger children and adolescents aged 0-18 years with advanced
105	chronic kidney disease (CKD, stage 3 or above), and those on immunosuppressive therapy,
106	on chronic dialysis and post-kidney transplant as they are clinically vulnerable. We evaluated
107	the immunogenicity and safety in participants who had initiated or completed a 3-dose
108	primary series of either CoronaVac (age <5 years), or BNT162b2 (0.1ml dose for 5-11 years,

109 and 0.3ml dose for 11-18 years).

CoronaVac and BNT162b2 in pediatric kidney patients

It is made available under a CC-BY-NC-ND 4.0 International license .

5

110 METHODS

111 Study Design

- 112 COVID-19 Vaccination in Adolescents and Children (COVAC; NCT04800133) is a non-
- 113 randomized study investigating the safety and immunogenicity of BNT162b2 and
- 114 CoronaVac, in healthy children and adolescents or those with pediatric illnesses as
- 115 previously described.^{10,13,14} The study was approved by the University of Hong Kong/Hong
- 116 Kong West Cluster Hospital Authority Institutional Review Board (UW21-157).

117

118 Participants

119 The current analysis included children and adolescents, aged 0-18 years, with advanced

120 chronic kidney disease (CKD, stage 3 or above), and those on immunosuppressive therapy,

121 on chronic dialysis and post-kidney transplant. All patients received at least two doses of

- 122 COVID-19 vaccine at the time of analysis. Participants with no known history of kidney
- 123 diseases were excluded from this analysis.
- 124

125 **Procedures**

126 Potential participants were recruited by pediatricians from the Pediatric Nephrology Centre, 127 Hong Kong Children's Hospital and the Department of Pediatrics and Adolescent Medicine, 128 Queen Mary Hospital in Hong Kong. The Pediatric Nephrology Centre in Hong Kong 129 Children's Hospital is the territory-wide, designated pediatric referral center for complicated 130 kidney diseases and chronic kidney replacement therapy, including dialysis and transplant. 131 Clinicians obtained informed consent from participants aged 18 years. Informed assent was 132 obtained from participants aged below 18, and consent was obtained from their parents or 133 legally acceptable representatives. Participants were either unvaccinated, or partially 134 vaccinated at the time of enrollment. Demographic information was reported by participants, 135 and clinical information were extracted from their health records. In our study, 0.5ml 136 CoronaVac was offered to participants aged below 5 years, 0.1ml BNT162b2 was offered to

137	participants aged 5-11 years as the original pediatric formulation was not available in Hong
138	Kong, and 0.3ml BNT162b2 was offered to participants aged 11-18 years. Participants who
139	received an alternative COVID-19 vaccine as the first or second dose prior to joining the
140	study would complete the remaining doses with the vaccine brand indicated for their age in
141	our study protocol. Additional consent and assent were obtained for dosage switching to
142	0.3ml for participants who became 12 years old after initiating the primary series. CoronaVac
143	and BNT162b2 were administered via the intramuscular route to the deltoid or the
144	anterolateral thigh, or, in some for 0.3ml BNT162b2, by an intradermal inoculator
145	(MicronJet600, NanoPass Technologies, Nes Ziona, Israel) to the deltoid. Doses 2 and 3
146	were given at least 14 and 28 days after the preceding dose. Vaccination was deferred in
147	patients with SARS-CoV-2 infection and was resumed or initiated 28 days later. All
148	participants were observed by a nurse or pediatrician after each dose for at least 15 minutes
149	after vaccination on site. Blood-taking and safety data collection were performed pre-dose 1,
150	pre-dose 2, post-dose 2 (14-42 days after dose 2), pre-dose 3 (blood-taking was only
151	performed for participants who received dose 3 more than 56 days after their post-dose 2
152	visit), and post-dose 3 (14-42 days after dose 3).
153	
154	Immunogenicity
155	Humoral
156	Primary outcomes on humoral immunogenicity included wild-type (WT, i.e. ancestral) Spike
157	receptor-binding domain (S-RBD) IgG ELISA and WT surrogate virus neutralization test
158	(sVNT). While the S-RBD IgG is a binding antibody assay, the sVNT is a functional antibody
159	assay which reflects blocking of S-RBD and human ACE2 receptor by vaccinee sera and
160	correlates with the gold-standard plaque reduction neutralization test. ¹⁵ Secondary outcome
161	was Omicron BA.1 sVNT. In-house WT S-RBD IgG enzyme-linked immunosorbent assay

- 162 (ELISA) were carried out as previously published.^{13,16} sVNT was conducted as per
- 163 manufacturer's instructions (GenScript Inc, Piscataway, USA).¹⁶

It is made available under a CC-BY-NC-ND 4.0 International license .

1	64
---	----

165 Cellular

166	Primary outcomes on cellular immunogenicity included antiviral cytokine-expressing (IFN- $\gamma^{\!\!+}$
167	or IL-2 ⁺) helper (CD4 ⁺) or cytotoxic (CD8 ⁺) T cell responses against SARS-CoV-2 S (and N
168	and M) proteins. They were examined by intracellular cytokine staining on flow cytometry
169	after stimulation with SARS-CoV-2 15-mer peptide pool(s) (Miltenyi Biotec, Bergisch
170	Gladbach, Germany) as described previously. ^{13,14,17} SARS-CoV-2 S peptide pool was used
171	for BNT162b2 while S, N and M peptide pools were used for CoronaVac as it is an
172	inactivated whole-virus vaccine. Frequencies of T cell responses against S, N and M peptide
173	pools were summated for CoronaVac. Secondary outcomes on cellular immunogenicity
174	included T cell responses to stimulation by BA.1 S (and N and M) mutation pools, which
175	consists of 15-mer peptides spanning the regions with BA.1-associated mutations only, were
176	examined with WT reference pools consisting of WT sequences in the same regions as the
177	comparator (Miltenyi Biotec, Bergisch Gladbach, Germany for S mutation pools and
178	ChinaPeptides, Shanghai, China for N and M mutation pools). ^{14,17}
179	
180	Analysis
181	Outcome data on immunogenicity were transformed by taking natural logarithm of the values
182	and compared longitudinally using paired t test. Negative values, i.e., those below the limit of
183	detection (LOD), limit of quantification (LOQ) or cut-off, were imputed as half the limit or cut-
184	off and included in the analyses. Certain WT T cell and Omicron-specific antibody and T cell
185	responses could only be performed in participants with sufficient blood sample volume.
186	Additional details are available in the Supplemental Methods.
187	
188	Safety and reactogenicity
189	Participants reported pre-specified adverse reactions (ARs) in an online or paper-based

190 diary for 7 days after vaccination. Unsolicited adverse events (AEs) were captured for up to

It is made available under a CC-BY-NC-ND 4.0 International license .

191	28 days after	each dose. S	evere AEs,	including	life-threatening	complications.	unanticipated
	,		,			· · · · · · · · · · · · · · · · · · ·	

- 192 or prolonged hospitalizations, disabilities, deaths and birth defects of their offspring, or
- breakthrough COVID-19, would be monitored for 3 years after vaccination. We also
- 194 monitored graft rejection among kidney transplant recipients and disease flare among those
- 195 with glomerular disease following vaccination. Adverse events reported were reviewed by
- 196 investigators, who determined any possibility of causal relationship with the study vaccine.

It is made available under a CC-BY-NC-ND 4.0 International license .

197 RESULTS

198 Participant composition

- 199 A total of 64 children and adolescents with kidney diseases (mean age 12.2, interquartile
- 200 range 9.4-16.2, and 32 male) received at least one dose of COVID-19 vaccine, including 5
- 201 aged 1-5 years for CoronaVac, 25 aged 5-11 years for 0.1ml BNT162b2, and 34 aged 11-18
- 202 years for 0.3ml BNT162b2 (Table 1). Thirteen patients were on dialysis, 15 patients
- 203 underwent kidney transplant, and 31 patients were on immunosuppressives alone at the
- 204 time of dose 1. All participants had Asian heritage. The details of these patients, grouped
- 205 according to their treatment, are summarized in Table S1. Five patients aged 14-18 years
- 206 elected to receive dose 3 BNT162b2 intradermally.
- 207

208

209 We studied antibody responses as they have been shown to correlate with vaccine efficacy against symptomatic COVID-19.¹⁸ We tracked antibody responses against WT SARS-CoV-210 211

Primary immunogenicity analysis of longitudinal antibody responses by vaccine type

2, including S-RBD IgG for binding antibody and sVNT for neutralization, longitudinally from

212 the pre-vaccine baseline to post-dose 3 by vaccine type in Fig. 1A and 1B respectively. S-

213 RBD IgG and sVNT responses rose significantly for all 3 vaccine types/ages after 3 doses

214 when compared to pre-dose 1 on paired t test after natural logarithmic transformation.

215 For patients who received the 3-dose primary series of CoronaVac (aged <5 years), all

216 children tested positive for S-RBD IgG (above LOD of 0.5, considered 'seropositive') and

217 had a high geometric mean sVNT% level of 94.0%. For patients who received the 3-dose

218 primary series of BNT162b2, 73.9% and 93.8% of the participants aged 5-11 years (who

219 received 0.1ml BNT162b2) were seropositive after doses 2 and 3, with geometric mean

220 sVNT% levels of 51.7% and 78.6%. These figures were similar to 11-18 years age group

221 (who received 0.3ml BNT162b2) where 81.8% and 90.9% of the participants were

222 seropositive, with geometric mean sVNT% levels of 60.5% and 80.0% after doses 2 and 3

223 respectively. Compared against 2 doses only, an additional third dose of 0.1ml and 0.3ml

It is made available under a CC-BY-NC-ND 4.0 International license .

224	BNT162b2 both elicited significant increases in S-RBD IgG and sVNT. Four patients who
225	received 2 intramuscular and 1 intradermal dose of 0.3ml BNT162b2 had a high geometric
226	mean sVNT% level of 95.7% post-dose 3. S-RBD IgG and sVNT responses were also
227	presented by kidney replacement therapy status in Table 2.
228	
229	Primary immunogenicity analysis of longitudinal T cell responses by vaccine type
230	We also studied T cell responses as they protect against progression to severe COVID-19. ¹⁹
231	For patients who received CoronaVac (< 5 years), IFN- γ^+ antiviral CD4 ⁺ helper and CD8 ⁺
232	cytotoxic T cell responses against SARS-CoV-2 S, N and M proteins were examined
233	longitudinally in Fig 2. In addition, $CD4^+$ and $CD8^+T$ cells expressing another antiviral
234	cytokine, IL-2, were also studied (Fig. S1A-D). In patients who received CoronaVac (<5
235	years), we detected a significant increase of SNM-specific IFN- γ^+ CD4 ⁺ T cell response (Fig.
236	2B). Other T cell responses also trended to increase, albeit insignificantly. Yet, all 5 patients
237	who received 3 doses of CoronaVac were positive for either S-specific or SNM-specific IFN-
238	γ^+ CD4 ⁺ and CD8 ⁺ T cells.
239	
240	For patients who received BNT162b2, T cell response against S protein only was examined.
241	After 3 doses of BNT162b2, we detected significant increases in all S-specific IFN- $\gamma^{\scriptscriptstyle +}$ and IL-
242	2^+ CD4 ⁺ and CD8 ⁺ T cell responses (Fig. 2A, 2C), except for S-specific IL-2 ⁺ CD8 ⁺ T cell
243	response in those aged 5-11 years who received 0.1ml BNT162b2 (Fig. S1). Four patients
244	who received an intradermal dose 3 of 0.3ml BNT162b2 appeared to have a similar level of
245	T cell responses as those who received intramuscular dose 3.
246	
247	Antibody and T cell responses against Omicron BA.1
248	As a secondary outcome, Omicron BA.1 neutralization was evaluated by sVNT. When
249	compared with paired WT sVNT, we found a significant lower sVNT% level against Omicron

250 BA.1 following dose 2 (64.1% vs 18.5%, P<0.0001) and dose 3 (84.0% vs 27.2%, P<0.0001)

It is made available under a CC-BY-NC-ND 4.0 International license .

(Fig. 3A), indicating that BA.1 markedly evades neutralization compared to WT in kidney
patients. However, we observed a significant increase in geometric mean BA.1 sVNT% level

- with dose 3 (post-dose 2 vs post-dose 3, 18.5% vs 27.2%, P=0.006).
- 254
- We then assayed IFN- γ^+ CD4⁺ and CD8⁺ T cells responses against Omicron BA.1 mutations in S, N and M after 2 doses of vaccine. Notably, T cell responses against Omicron BA.1 and WT S protein were comparable after 2 doses of any vaccine (Fig. 3B). Similarly, in patients aged <5 years who received CoronaVac, N-specific and M-specific T cell responses were comparable between Omicron BA.1 and WT (Fig. 3C-D), suggesting T cell responses were not diminished by mutations in Omicron BA.1.
- 261

262 Correlation of immunogenicity with vaccine type and treatment modality

263 We explored correlation of immunogenicity with age or type of vaccine, and treatment as a

secondary analysis. We focused on post-dose 2 WT sVNT because antibody assays are

265 more sensitive than T cell assays and correlates with plaque neutralization better than S-

RBD IgG. No correlation with immunogenicity was found for age or type of vaccine.

267 However, compared to non-dialysis patients who were not on immunosuppressives, a

significantly lower sVNT level was detected for both kidney transplant recipients (geometric

mean ratio of sVNT% 0.38, 95% CI 0.16-0.90; P=0.03) and patients who received rituximab

within 1 year preceding vaccination (geometric mean ratio of sVNT% 0.32, 95% CI 0.13-

271 0.77; P=0.02) (Fig. 4). In contrast, patients on chronic dialysis demonstrated a similar

antibody response to non-dialysis patients not on immunosuppression (P=0.27).

273

274 Breakthrough COVID-19 cases and hybrid immunity

From January 2022, Hong Kong was hit by the first major wave of COVID-19 resulting from

- 276 Omicron BA.2 variant. Eleven patients (17% of all participants) reported COVID-19 during
- that time, including 7 (11%) before and 4 (6%) after initiating COVID-19 vaccination. All

278	patients reported mild COVID-19 without the need of hospitalization. No mortality was
279	reported. Two patients had a longer clinical course with rapid antigen test positivity for 14
280	and 17 days. They were both unvaccinated and treated with immunosuppressive therapy for
281	underlying glomerular disease. Two patients had breakthrough COVID-19 after completing 3
282	doses, and both had a high WT sVNT% level above 90% (93.7% and 90.6%) tested shortly
283	before breakthrough infection. Both patients were managed conservatively without
284	complications.

285

286 We also investigated the effect of hybrid immunity, which refers to the synergized immune 287 response from both vaccination and infection, in patients who were infected prior to 288 vaccination (Fig. S2A-C). Before vaccination, only two patients out of 7 seroconverted to 289 infection alone, and one of them had a positive yet weak neutralizing response (Fig. S2A). 290 After receiving 2 doses of vaccine, infected patients showed significantly boosted S-RBD 291 IgG and WT sVNT responses (Fig. S2A). When compared to uninfected patients who 292 received 2 doses of vaccine, infected and vaccinated patients also had a higher Omicron 293 BA.1 sVNT (Fig. S2B). For T cell responses among infected patients, S-specific IFN- γ^+ CD4⁺ 294 T cells were significantly increased after 2 doses compared to pre-dose 1, and S-specific 295 IFN- γ^{+} CD8⁺ T cells showed an upward trend as well (Fig. S2C).

296

297 Safety and reactogenicity

We tracked ARs for 7 days and AEs for 28 days after each dose. COVID-19 vaccination appeared tolerable in our patients. Patients receiving either vaccine brand mainly reported mild and moderate ARs (Fig. 5). Two and 5 AEs were reported within 28 days after 0.1ml and 0.3ml BNT162b2, including 2 reports after dose 1 and 5 reports after dose 2. They included chest discomfort (n=1), palpitations (n=2), tachycardia (n=1), epistaxis (n=1), insomnia (n=1), and tinnitus (n=1). All AEs were grade 1 except for the report of tinnitus,

304 which was grade 2. None of the kidney transplant recipients developed graft rejection during

It is made available under a CC-BY-NC-ND 4.0 International license .

305	the follow-up period. Of the 31 non-dialysis patients with glomerular disease, 2 patients
306	(6.4%) developed disease relapse closely following vaccination, 1 of whom required
307	hospitalization. Two more patients experienced relapse, but their relapses could be
308	attributable to acute COVID-19 and to B cell reconstitution 12 months after rituximab,
309	respectively. Four patients reported a non-fatal resolved severe AE after study vaccine
310	administration, including one for nephrotic syndrome relapse, one with suspected
311	myopericarditis, one with prolonged post-vaccine fever and one with catheter-associated
312	infection. All patients with an SAE recovered without complications. More details regarding
313	adverse events are available in Supplemental Information.

It is made available under a CC-BY-NC-ND 4.0 International license .

314 DISCUSSION

328

315 In this study, we demonstrated that an accelerated, 3-dose COVID-19 vaccine schedule with 316 CoronaVac (<5 years) and BNT162b2 at age-appropriate dose (5-18 years) elicited 317 favorable antibody and T cell responses. However, weaker antibody responses were found 318 in patients who received kidney transplant or rituximab. Although Omicron BA.1 mutations 319 led to partial neutralization escape, dose 3 significantly enhanced neutralization capacity. 320 Importantly, T cell responses against Omicron BA.1 were comparable to that with WT, 321 suggesting effective protection from severe COVID-19 by vaccination. 322 323 We showed a significant induction of S-RBD IgG and WT sVNT antibody responses 324 regardless of vaccine type and age. Antibody response is the first line of defense against

infection and has been shown to correlate with efficacy against COVID-19,¹⁸ Therefore, our

results suggest that 3 doses of COVID-19 vaccines could offer protection against COVID-19

have a 100% seropositivity after a single dose of BNT162b2,¹³ 4 out of 47 (9%) patients

in children and adolescents with kidney diseases. In contrast to healthy adolescents who

329 failed to develop antibody responses after 3 doses of vaccine. Similarly, studies on adult

330 patients who are on dialysis or post-kidney transplant also demonstrated weak antibody

331 responses, related to the immunosuppressed state in kidney failure and immunosuppressive

therapy.^{20,21} In our study, kidney transplant recipients and patients receiving rituximab for

333 glomerular disease were identified to have lower antibody response. This is likely to be due

to intense humoral immunosuppression by triple therapy post-transplant or by rituximab.

Rituximab has emerged as an important therapeutic option in several pediatric immune mediated glomerular diseases, such as idiopathic nephrotic syndrome and ANCA-associated
 vasculitis glomerulonephritis.^{2,22,23} Our data showed that rituximab exposure up to 1 year

338 prior to vaccination resulted in poor immunogenicity. Furthermore, patients with glomerular

disease are at risk of relapse and often require multiple courses of rituximab to maintain

340 disease remission.²² Therefore, the timing of vaccination and rituximab should be

It is made available under a CC-BY-NC-ND 4.0 International license .

individualized, balancing the risk of infection and disease relapse. Fortunately, our current
findings did not suggest an overtly increased risk of graft rejection and disease relapse
following vaccination, indicating the safety of COVID-19 vaccination in children and

345

344

adolescents with kidney diseases.

346 The SARS-CoV-2 Omicron variant has caused repeated surges in COVID-19 cases and 347 hospitalizations across the globe, with more than 30 mutations in S protein which cause 348 extensive neutralization escape and reduce the effectiveness of COVID-19 vaccines.²⁴⁻²⁶ 349 According to our data, when compared with WT sVNT, we found that a significantly lower 350 sVNT% level against Omicron BA.1 following doses 2 and 3, signifying partial neutralization 351 escape. However, neutralization capacity was significantly enhanced by dose 3 from 18.5% 352 to 27.2%. We postulate that further booster doses may further optimize the immunogenicity 353 and protection in children and adolescents with kidney diseases, as a fourth dose has been 354 found to seroconvert adult kidney transplant recipients who were seronegative after 3 355 doses.²⁷ Interestingly, our data suggested that T cell responses remained robust against Omicron even with a WT vaccine, in line with observations in healthy adolescents.^{14,17} T cell 356 responses against SARS-CoV-2, including towards non-S proteins,²⁸ may protect against 357 progression to severe COVID-19 after a breakthrough infection,¹⁹ even against variants of 358 359 concerns with major neutralization escape.

360

We only observed mild infections after vaccination in our cohort. It was known that either a post-vaccine breakthrough infection or vaccination following infection improves the magnitude and diversity of immune response, leading to hybrid immunity that could be longer-lasting and cross-reactive towards novel variants.²⁹ Our data showed that only 28% patients seroconverted to infection alone. Yet, Omicron BA.1 sVNT after 2 doses among infected patients was significantly higher than that of uninfected vaccinated patients. This further supports the need of vaccination in pediatric kidney patients even after SARS-CoV-2

CoronaVac and BNT162b2 in pediatric kidney patients

It is made available under a CC-BY-NC-ND 4.0 International license .

368	infection, as this will generate hybrid immunity, and enhance protection against future
369	variants. Although few of our vaccinated participants experienced a breakthrough infection,
370	allow us to investigate their immune responses, those vaccinated and experienced a
371	breakthrough infection should likewise complete all recommended doses for maximal
372	protection. Nonetheless, we advocate for continued personal hygiene measures to minimize
373	the chance of a severe breakthrough COVID-19 in children and adolescents with kidney
374	diseases.

375

376 In this study, we vaccinated young children under age 5 with full-dose CoronaVac, an 377 inactivated COVID-19 vaccine, and children aged 5-11 years with 0.1ml BNT162b2. Real-378 world effectiveness data in Hong Kong collected during the BA.2.2 wave showed 379 comparable effectiveness against severe and fatal COVID-19 after 3 doses of either vaccine brand in adults,²⁶ and against infection after 2 doses of either vaccine brand in children and 380 adolescents.⁸ The investigators preferred BNT162b2 for children and adolescents with 381 382 kidney diseases as there were more effectiveness data on mRNA COVID-19 vaccines in immunocompromised patients.^{30,31} Yet, the pediatric formulation of BNT162b2 was not made 383 384 available to Hong Kong, and we adopted dosage reduction, injecting 0.1ml for an equivalent 385 potency of 10mcg, with reference to United Kingdom Joint Committee on Vaccination and Immunization advice for children in a clinically risk group in December 2021.³² In children 386 387 below 5 years, as safety and immunogenicity data were published for CoronaVac and not for BNT162b2 at the time of the Omicron BA.2.2 wave in Hong Kong,⁵ we offered CoronaVac to 388 389 young children and infants with kidney diseases urgently. Our findings suggest both 0.1ml 390 BNT162b2 and CoronaVac were safe and immunogenic and support their use in children 391 with kidney diseases.

392

Furthermore, due to the rapid Omicron BA.2 wave in Hong Kong during study period, we
administered the vaccines using an accelerated regimen, with 14-day interval between

It is made available under a CC-BY-NC-ND 4.0 International license .

17

395	doses 1 and 2, and 28-day interval between doses 2 and 3. While longer prime-boost
396	intervals are associated with better immunogenicity in general, ³³ seronegativity after just 1 or
397	2 doses was common in our study, and it was important for our vulnerable patients to
398	immediately attain a higher level of protection within a short timeframe before catching
399	Omicron. We showed that the accelerated regimen was still able to elicit antibody and T cell
400	responses significantly in children and adolescents with kidney diseases and speculate that
401	their immune responses will also be boosted by breakthrough infections and booster doses.
402	
403	Moreover, while our study conducted antibody and T cell testing under a research protocol,
404	clinicians might be tempted to base their decisions of vaccination or boosting on SARS-CoV-
405	2 antibody testing. However, the 2 participants who received all 3 doses of vaccines prior to
406	infection both showed high WT sVNT antibody response (>90%) prior to acute COVID-19.
407	This suggests antibody testing in an individual patient cannot be used to predict
408	susceptibility to infection nor to guide booster decision.
409	
410	Our study had strengths and limitations. We tracked antibody and T cell responses
411	longitudinally in a relatively large cohort of vaccinated children and adolescents with different
412	kidney diseases and treatments aged 1-18 years and provided the first Omicron-specific
413	neutralization and T cell responses in this patient population. We could not assess clinical
414	effectiveness, nor compare immunogenicity of vaccine brands in the same age groups.
415	Sample number available for a particular test and timepoint was limited by the blood volume
416	collected and completion of study visit by the participant. As we used 0.1ml dose of the adult
417	formulation for BNT162b2, reactogenicity and immunogenicity could potentially differ from
418	that of the actual pediatric formulation.

419

In conclusion, our findings support that an accelerated, 3-dose primary series of mRNA or
 inactivated COVID-19 vaccines is safe and immunogenic for children and adolescents with

It is made available under a CC-BY-NC-ND 4.0 International license .

- 422 kidney diseases, especially among kidney transplant recipients and patients receiving
- 423 rituximab therapy. Although neutralization response against Omicron was reduced, T cell
- 424 response was preserved and may offer protection to children and adolescents with kidney
- 425 diseases from severe COVID-19. Further studies are needed to shed light on the
- 426 immunogenicity of a fourth dose and hybrid immunity in immunocompromised children in the
- 427 future.

It is made available under a CC-BY-NC-ND 4.0 International license .

428 STATEMENT OF CONTRIBUTION

- 429 Y.L. Lau conceptualized the study. Y.L. Lau, M. Peiris, W. Tu, D. Leung, J.S. Rosa Duque,
- 430 and X. Mu designed the study. Y.L. Lau led the acquisition of funding. Y.L. Lau, W. Tu, and
- 431 M. Peiris supervised the project. S.M. Chan, D. Leung, X. Mu, S.M.S. Cheng, I.Y.S. Tam,
- 432 and J.H.Y. Lam led the study administrative procedures. A.L.T. Ma, Y.L. Lau, J.S. Rosa
- 433 Duque, E.Y.H. Chan, S. Chim, F.T.W. Ho, P.C. Tong, W.M. Lai, and M.H.L. Lee provided
- 434 study-related clinical assessments and follow-up. D. Leung, S.M. Chan, S.T.K. Sze, J.H.Y.
- 435 Lam, J.S. Rosa Duque, and Y.L. Lau collected clinical safety data. S.M.S. Cheng, L.C.H.
- 436 Tsang, K.K.H. Kwan, and M. Peiris developed and performed S-RBD IgG and sVNT. X. Mu,
- 437 Y. Chung, H.H.W. Wong, A.M.T. Lee, W.Y. Li, and W. Tu developed and performed the T
- 438 cell assays. D. Leung, D.H.L. Lee, and J.H.Y. Lam curated, analyzed, and visualized the
- data. D. Leung, X. Mu, S.M.S. Cheng, J.S. Rosa Duque, D.H.L. Lee, J.H.Y. Lam, and S.M.
- 440 Chan validated the data. D. Leung and E.Y.H. Chan drafted the manuscript and were
- supervised by A.L.T. Ma, J.S. Rosa Duque, and Y.L. Lau, with input from X. Mu, and S.M.S.
- 442 Cheng. All authors reviewed and approved the final manuscript.
- 443

444 **ACKNOWLEDGEMENTS**

- 445 We thank the staff at Community Vaccination Centers at Ap Lei Chau Sports Centre,
- 446 Gleneagles Hospital Hong Kong, and Sun Yat-Sen Memorial Park Sports Centre. The
- 447 investigators are grateful to all clinical research team members and laboratory staff of
- 448 Department of Pediatrics and Adolescent Medicine of the University of Hong Kong, for their
- research support. We are most thankful to the study participants, as well as clinicians and
- 450 laboratory staff who have provided clinical care and testing to the patients.

451

452 **DISCLOSURES**

453 The authors declare no conflicts of interest.

It is made available under a CC-BY-NC-ND 4.0 International license .

455 FUNDING

- 456 This study was supported by the research grants COVID19F02, COVID19F10, and
- 457 COVID19F12 from the Hong Kong SAR Government, which was not involved in the study
- 458 design, performance, interpretation, or publication of this project.
- 459

460 **DATA SHARING**

- 461 All requests to share the pseudonymized data underlying the conclusions of this paper from
- researchers will be facilitated by the authors, subject to ethics approval. Enquiries should be
- 463 addressed to <u>lauylung@hku.hk</u>.

464

465 SUPPLEMENTAL MATERIALS

- 466 Supplemental Methods
- 467 Supplemental Information: Safety and Reactogenicity

It is made available under a CC-BY-NC-ND 4.0 International license .

468 **REFERENCES**

Jdiaa, S.S., Mansour, R., El Alayli, A., Gautam, A., Thomas, P., and Mustafa, R.A. (2022).
 COVID-19 and chronic kidney disease: an updated overview of reviews. J Nephrol *35*, 69-85.
 10.1007/s40620-021-01206-8.

Chan, E.Y.H., Yap, D.Y.H., Wong, W.H.S., Ho, T.W., Tong, P.C., Lai, W.M., Chan, T.M., and
Ma, A.L.T. (2022). Demographics and long-term outcomes of children with end-stage kidney disease:
A 20-year territory-wide study. Nephrology (Carlton) *27*, 171-180. 10.1111/nep.14007.

Frenck, R.W., Jr., Klein, N.P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J.L.,
 Walter, E.B., Senders, S., Bailey, R., et al. (2021). Safety, Immunogenicity, and Efficacy of the
 BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med *385*, 239-250. 10.1056/NEJMoa2107456.

Walter, E.B., Talaat, K.R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G.C., Barnett,
 E.D., Muñoz, F.M., Maldonado, Y., Pahud, B.A., et al. (2022). Evaluation of the BNT162b2 Covid-19
 Vaccine in Children 5 to 11 Years of Age. N Engl J Med 386, 35-46. 10.1056/NEJMoa2116298.

Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., Lian, X., Jiao, W., Wang, L., et
al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine
(CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2
clinical trial. The Lancet Infectious Diseases *21*, 1645-1653. 10.1016/s1473-3099(21)00319-4.

Jara, A., Undurraga, E.A., Zubizarreta, J.R., Gonzalez, C., Acevedo, J., Pizarro, A., Vergara,
 V., Soto-Marchant, M., Gilabert, R., Flores, J.C., et al. (2022). Effectiveness of CoronaVac in children
 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nat Med. 10.1038/s41591-022 01874-4.

Florentino, P., Alves, F., Cerqueira-Silva, T., Oliveira, V.d.A., Júnior, J.B., Jantsch, A., Penna,
 G., Boaventura, V., Werneck, G., Pearce, N., et al. (2022). Vaccine effectiveness of CoronaVac
 against symptomatic and severe COVID-19 among children in Brazil during the Omicron period. Res
 Sq. 10.21203/rs.3.rs-1604882/v1.

Leung, D., Duque, J.R., Yip, K.M., So, H.K., Wong, W., and Lau, Y.L. (2022). Effectiveness of
 BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during
 Omicron BA.2 wave in Hong Kong. Res Sq. 10.21203/rs.3.rs-1856540/v1.

496 9. Centre for Health Protection, Hong Kong. Recommendation for additional dose(s) of COVID 497 19 vaccination. (2022).

Ma, A.L.-T., Leung, D., Chan, E.Y.-H., Chim, S., Cheng, S., Ho, F.T.-W., Lai, W.-M., Tong, P.C., Lee, M.H.-L., Wong, W.H.-S., et al. (2022). Antibody responses to 2 doses of mRNA COVID-19
vaccine in pediatric patients with kidney diseases. Kidney International *101*, 1069-1072.

501 11. Crane, C., Phebus, E., and Ingulli, E. (2022). Antibody response to 2- and 3-dose SARS-CoV 2 mRNA vaccination in pediatric and adolescent kidney transplant recipients. Pediatr Nephrol.
 503 10.1007/s00467-022-05661-8.

504 12. Crane, C., Phebus, E., and Ingulli, E. (2022). Immunologic response of mRNA SARS-CoV-2
 505 vaccination in adolescent kidney transplant recipients. Pediatr Nephrol *37*, 449-453. 10.1007/s00467 506 021-05256-9.

13. Rosa Duque, J., Wang, X., Leung, D., Cheng, S., Cohen, C., Mu, X., Hachim, A., Zhang, Y.,
Chan, S.-M., Chaothai, S., et al. (2022). Immunogenicity and reactogenicity of SARS-CoV-2 vaccines
BNT162b2 and CoronaVac in healthy adolescents. Nat Commun *13*, 3700.

510 https://doi.org/10.1038/s41467-022-31485-z.

Leung, D., Cohen, C.A., Mu, X., Rosa Duque, J., Cheng, S.M., Wang, X., Wang, M., Zhang,
 W., Zhang, Y., Tam, I.Y., et al. (2022). Immunogenicity Against Wild-Type and Omicron SARS-CoV-2
 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents. SSRN: Cell Press Sneak
 Peek. <u>https://ssrn.com/abstract=4115862</u>.

Perera, R., Ko, R., Tsang, O.T.Y., Hui, D.S.C., Kwan, M.Y.M., Brackman, C.J., To, E.M.W.,
 Yen, H.L., Leung, K., Cheng, S.M.S., et al. (2021). Evaluation of a SARS-CoV-2 Surrogate Virus
 Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. J Clin
 Microbiol *59*. 10.1128/JCM.02504-20.

Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C., Yuan, M., Leung, W.S.,
 Chan, J.M., Chik, T.S., et al. (2020). Serological assays for severe acute respiratory syndrome
 coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 25. 10.2807/1560 7917.ES.2020.25.16.2000421.

Mu, X., Cohen, C.A., Leung, D., Duque, J.S.R., Cheng, S.M.S., Chung, Y., Wong, H.H.W.,
Lee, A.M.T., Li, W.Y., Tam, I., et al. (2022). Antibody and T cell responses against wild-type and
Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescents. Res Sq.
10.21203/rs.3.rs-1961385/v1.

18. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are highly
predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med *27*, 1205-1211.
10.1038/s41591-021-01377-8.

531 19. Openshaw, P.J.M. (2022). Using correlates to accelerate vaccinology. Science 375, 22-23.
532 10.1126/science.abn0007.

Schrezenmeier, E., Rincon-Arevalo, H., Stefanski, A.L., Potekhin, A., Straub-Hohenbleicher,
H., Choi, M., Bachmann, F., Pross, V., Hammett, C., Schrezenmeier, H., et al. (2021). B and T Cell
Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. J Am Soc
Nephrol. 10.1681/ASN.2021070966.

537 21. Praet, J.V., Reynders, M., Bacquer, D.D., Viaene, L., Schoutteten, M.K., Caluwe, R., Doubel,
538 P., Heylen, L., Bel, A.V.D., Vlem, B.V., et al. (2021). Predictors and Dynamics of the Humoral and
539 Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter
540 Observational Study. Journal of American Society of Nephrology *32*, 3208-3220.

Chan, E.Y.-h., Yu, E.L.M., Angeletti, A., Arslan, Z., Basu, B., Boyer, O., Chan, C.-Y., Colucci,
M., Dorval, G., Dossier, C., et al. (2022). Long-Term Efficacy and Safety of Repeated Rituximab to
Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. Journal of
the American Society of Nephrology *33*, 1193-1207. 10.1681/asn.2021111472.

Marlais, M., Wlodkowski, T., Printza, N., Kronsteiner, D., Krisam, R., Sauer, L., Aksenova, M.,
Ashoor, I., Awan, A., Bacchetta, J., et al. (2022). Clinical Factors and Adverse Kidney Outcomes in
Children With Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. Am J Kidney Dis.
10.1053/j.ajkd.2022.05.013.

549 24. Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J.E.,
550 Cromer, D., Scheepers, C., Amoako, D.G., et al. (2022). Omicron extensively but incompletely
551 escapes Pfizer BNT162b2 neutralization. Nature *602*, 654-656. 10.1038/s41586-021-04387-1.

Cheng, S.M.S., Mok, C.K.P., Leung, Y.W.Y., Ng, S.S., Chan, K.C.K., Ko, F.W., Chen, C., Yiu,
K., Lam, B.H.S., Lau, E.H.Y., et al. (2022). Neutralizing antibodies against the SARS-CoV-2 Omicron
variant following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med.
10.1038/s41591-022-01704-7.

McMenamin, M.E., Nealon, J., Lin, Y., Wong, J.Y., Cheung, J.K., Lau, E.H.Y., Wu, P., Leung,
G.M., and Cowling, B.J. (2022). Vaccine effectiveness of one, two, and three doses of BNT162b2 and
CoronaVac against COVID-19 in Hong Kong: a population-based observational study. The Lancet
Infectious Diseases. 10.1016/s1473-3099(22)00345-0.

Masset, C., Benotmane, I., Dantal, J., Garandeau, C., Gauthier-Vargas, G., Cantarovich, D.,
Meurette, A., Giral, M., Caillard, S., and Blancho, G. (2022). A fourth SARS-CoV-2 mRNA vaccine in
strictly seronegative kidney transplant recipients. Kidney Int *101*, 825-826. 10.1016/j.kint.2022.01.017.

Peng, Y., Felce, S.L., Dong, D., Penkava, F., Mentzer, A.J., Yao, X., Liu, G., Yin, Z., Chen,
J.L., Lu, Y., et al. (2022). An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls
viral replication and is associated with less severe COVID-19 disease. Nat Immunol 23, 50-61.
10.1038/s41590-021-01084-z.

29. Cao, Y., Song, W., Wang, L., Liu, P., Yue, C., Jian, F., Yu, Y., Yisimayi, A., Wang, P., Wang,
Y., et al. (2022). Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75.
bioRxiv, 2022.2007.2018.500332. 10.1101/2022.07.18.500332.

Oliver, M.J., Thomas, D., Balamchi, S., Ip, J., Naylor, K., Dixon, S.N., McArthur, E., Kwong,
 J., Perl, J., Atiquzzaman, M., et al. (2022). Vaccine Effectiveness Against SARS-CoV-2 Infection and
 Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada. J Am Soc Nephrol *33*,
 839-849. 10.1681/ASN.2021091262.

Sibbel, S., McKeon, K., Luo, J., Wendt, K., Walker, A.G., Kelley, T., Lazar, R., Zywno, M.L.,
 Connaire, J.J., Tentori, F., et al. (2022). Real-World Effectiveness and Immunogenicity of BNT162b2
 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. J Am Soc Nephrol 33, 49-57.
 10.1681/ASN.2021060778.

JCVI statement on COVID-19 vaccination of children and young people: 22 December 2021.
 <u>https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-</u>
 <u>children-and-young-people/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-22-</u>

581 <u>december-2021</u>.

33. Voysey, M., Costa Clemens, S.A., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K.,
Angus, B., Baillie, V.L., Barnabas, S.L., Bhorat, Q.E., et al. (2021). Single-dose administration and the
influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19
(AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet *397*, 881-891.

586 10.1016/s0140-6736(21)00432-3. 587

1 TABLE 1. Participant profile by vaccine type and age. eGFR (estimated glomerular filtration

2 rate) is estimated by modified Schwartz equation for participants below age 18 years and CKD-

3 EPI formula for those above. KRT, kidney replacement therapy

	All patients	CoronaVac, <5 years	BNT162b2, 5-11 years, 0.1ml	BNT162b2, 11-18 years, 0.3ml
Number of participants N	64	5	25	34
Age mean (interquartile range)	12.2 (9.4 – 16.2)	3.3 (3.1-3.6)	9.1 (8.6-12.1)	15.7 (10.5-16.4)
Sex male n:female n	32:32	2:3	12:13	18:16
Number of participants completing 2 doses n (%)	64 (100%)	5 (100%)	25 (100%)	34 (100%)
Number of participants completing 3 doses n (%)	51 (80%)	5 (100%)	17 (68%)	29 (85%)
Primary kidney diagnosis n	(%)			- ()
CAKUI	10 (16%)	1 (20%)	4 (16%)	5 (15%)
Glomerular diseases	36 (56%)	3 (60%)	15 (60%)	18 (53%)
Hereditary	11 (17%)	1 (20%)	4 (16%)	6 (18%)
Miscellaneous	7 (11%)	0 (0%)	2 (8%)	5 (15%)
Treatment modality n (%)				
No KRT	36 (56%)	4 (80%)	16 (64%)	16 (47%)
On immunosuppression	31 (48%)	2 (40%)	14 (56%)	15 (44%)
KRT		1		
Kidney transplant	15 (23%)	0 (0%)	7 (28%)	8 (24%)
Dialysis	13 (20%)	1 (20%)	2 (8%)	10 (29%)
Vintage of KRT	5.7 (1-18)	2 (2)	6.2 (2-10)	5.6 (1-18)
Concurrent immunosuppre	ssion within 3 month	s n (%)		
Mycophenolate mofetil	32 (50%)	1 (20%)	13 (52%)	18 (53%)
Prednisolone	38 (59%)	1 (20%)	15 (60%)	22 (65%)
Azathioprine	3 (5%)	0 (0%)	0 (0%)	3 (9%)
Cyclosporine A	2 (3%)	0 (0%)	1 (4%)	1 (3%)
Tacrolimus	29 (45%)	1 (20%)	13 (52%)	15 (44%)
Everolimus	4 (6%)	0 (0%)	3 (12%)	1 (3%)
Hydroxychloroquine	6 (9%)	0 (0%)	1 (4%)	5 (15%)
Rituximab	3 (5%)	1 (20%)	0 (0%)	2 (6%)
None	14 (22%)	3 (60%)	3 (12%)	8 (24%)
Immunosuppression within	1 year n (%)	I		
Rituximab	9 (14%)	1 (20%)	2 (8%)	6 (18%)
Kidney function and protein	nuria mean (range)	1	1	1
eGFR (ml/min/1.73m ²)	88.1 (20-234)	97.0 (20-234)	91.2 (20-184)	84.0 (24-145)
Urine protein/creatinine ratio (mg/mmol)	33.9 (1.6-140)	22.7 (14-32)	29.8 (1.6 -140)	40.2 (6-108)
Blood count and comorbidi	ties			
Hypertension n (%)	38 (59%)	4 (80%)	12 (48%)	22 (65%)
Absolute lymphocyte count (x10 ⁶ /ml) <i>mean (range)</i>	2.5 (0.48-6.47)	4.5 (3.27-6.47)	2.9 (1-5.59)	2.0 (0.48-5.18)

4 TABLE 2. Antibody responses including S-RBD IgG and surrogate virus neutralization

5 test (sVNT) against wild-type SARS-CoV-2 by treatment status. Number of seropositive

6 patients by S-RBD IgG were given by n/N (%) and geometric mean sVNT with 95% confidence

7 intervals (CIs) were shown. KRT, kidney replacement therapy

	No KRT			On KRT					
	No IS	Any IS	Rituximab	Dialysis	Transplant				
S-RBD IgG seropositivity (%)									
Pre-dose 2	4/4 (100%)	14/29 (48.3%)	2/9 (22.2%)	8/12 (66.7%)	3/12 (25.0%)				
Post-dose 2	5/5 (100%)	23/30 (76.7%)	5/9 (55.6%)	11/11 (100.0%)	10/15 (66.7%)				
Post-dose 3	4/4 (100%)	19/20 (95.0%)	3/4 (75.0%)	8/8 (100.0%)	9/11 (81.8%)				
Geometric mean sVNT% level (95% CI)									
Pre-dose 2	67.0% (47.3-100.6%)	28.6% (21.7-37.6%)	21.3% (12.5-36.4%)	39.4% (24.6-63.0%)	21.4% (14.1-32.4%)				
Post-dose 2	96.5% (95.0-97.9%)	57.2% (42.8-76.4%)	30.7% (15.6-60.6%)	91.5% (85.5%-97.9%)	37.0% (22.6- 60.6%)				
Post-dose 3	97.4% (96.1-98.8%)	86.5% (71.1-105.2%)	60.8% (13.8-267.9%)	95.9% (93.9-98.0%)	59.4% (35.9- 98.2%)				

It is made available under a CC-BY-NC-ND 4.0 International license .

9 FIG. 1. Antibody responses against wild-type SARS-CoV-2 including (A) S-RBD IgG for

10 binding and (B) surrogate virus neutralization test (sVNT) for neutralization. Matched pre-

- 11 dose 1 or post-dose 2 tests were compared with post-dose 3 by paired t test after natural
- 12 logarithmic transformation, and p values are denoted by asterisks (*, P<0.05; **, P<0.01; ****,
- 13 P<0.0001; ns, not significant). Geometric means (GM) are shown with center lines and stated
- 14 above each column. Limits of detection and quantification (LOD and LOQ) were drawn as grey
- 15 lines. Data points of patients who received intradermal 0.3ml BNT162b2 as dose 3 were
- 16 depicted as rhombi, and those of infected patients were drawn to be hollow beginning from after
- 17 the infection.



Humoral and Cellular Immunogenicity and Safety of 3 Doses of BNT162b2 and CoronaVac in Young Children and Adolescents with Kidney Diseases

It is made available under a CC-BY-NC-ND 4.0 International license .

19 FIG. 2. IFN- y^+ T cell responses against wild-type SARS-CoV-2 proteins. T cell responses 20 against S protein were tested for all participants while responses against S, N and M proteins 21 were only tested for CoronaVac. Matched pre-dose 1 and post-dose 3 tests were compared by 22 paired t test after natural logarithmic transformation, and p values are denoted by asterisks (*, P<0.05; **, P<0.01; ***, P<0.001; ns, not significant). Geometric means (GM) are shown with 23 center lines and stated above each column. Cut-offs were drawn as grey lines. Data points of 24 patients who received intradermal 0.3ml BNT162b2 as dose 3 were depicted as rhombi, and 25 26 those of infected patients were drawn to be hollow beginning from after the infection.



Humoral and Cellular Immunogenicity and Safety of 3 Doses of BNT162b2 and CoronaVac in Young Children and Adolescents with Kidney Diseases

It is made available under a CC-BY-NC-ND 4.0 International license .

FIG. 3. Antibody and T cell response against Omicron BA.1. Matched WT and BA.1 tests 28 29 were compared by paired t test after natural logarithmic transformation, and the p values are denoted by asterisks (**, P<0.01; ****, P<0.0001; ns, not significant). Geometric means (GM) 30 31 are shown with center lines and stated above each column. Limit of quantification (LOQ) and 32 cut-offs were drawn as grey lines. Data points were colored orange, navy blue and cyan according to vaccine type and age, referring to <5 years CoronaVac, 5-11 years 0.1ml 33 BNT162b2 and 11-18 years 0.3ml BNT162b2 respectively. Data points of patients who received 34 35 intradermal 0.3ml BNT162b2 as dose 3 were depicted as rhombi, and those of infected patients were drawn to be hollow beginning from after the infection. 36



Humoral and Cellular Immunogenicity and Safety of 3 Doses of BNT162b2 and CoronaVac in Young Children and Adolescents with Kidney Diseases

It is made available under a CC-BY-NC-ND 4.0 International license .

38 FIG. 4. Correlation of surrogate virus neutralization test (sVNT) % levels with vaccine

- 39 type (or age) and treatment. sVNT results at 1 month after 2 doses were compared by
- 40 unpaired t test after natural logarithmic transformation. KRT, kidney replacement therapy; IS,

41 immunosuppressives



It is made available under a CC-BY-NC-ND 4.0 International license .

43 FIG. 5. Adverse reactions (ARs) and antipyretic use reported 7 days after each dose by

- 44 vaccine type. Stacked bar chart shows ARs by maximal severity in different colors. C -
- 45 CoronaVac, 0.1ml or 0.3ml B BNT162b2.



It is made available under a CC-BY-NC-ND 4.0 International license .

47 **TABLE S1. Participant profile by treatment.** eGFR (estimated glomerular filtration rate) is

48 estimated by modified Schwartz equation for participants below age 18 years and CKD-EPI

49 formula for those above. KRT, kidney replacement therapy; NA - not applicable

	No KRT			On KRT					
Treatment	No IS	Any IS	Rituximab	Dialysis	Transplant				
Participants N	5	31	9	13	15				
Age mean (interquartile range)	6.5 (7.1-11.9)	11.9 (9.6-15.9)	13.4 (9.6-15.9)	14.3 (9.4-16.2)	12.9 (10.4-16.0)				
Sex male n:female n	4:1	15:16	3:6	4:9	9:6				
Vaccine and age									
CoronaVac, <5 years <i>n</i> (%)	2 (40%)	2 (6%)	1 (11%)	1 (8%)	0 (0%)				
BNT162b2, 5-11 years, 0.1ml <i>n (%)</i>	2 (40%)	14 (45%)	2 (22%)	2 (15%)	7 (47%)				
BNT162b2, 11-18 years, 0.3ml <i>n (%)</i>	1 (20%)	15 (48%)	6 (67%)	10 (77%)	8 (53%)				
Completed 2 doses n (%)	5 (100%)	31 (100%)	9 (100%)	13 (100%)	15 (100%)				
Completed 3 doses n (%)	4 (80%)	24 (77%)	5 (56%)	11 (85%)	12 (80%)				
Type of kidney disease n (%)									
CAKUT	3 (60%)	0 (0%)	0 (0%)	1 (8%)	6 (40%)				
Glomerular diseases	1 (20%)	30 (97%)	9 (100%)	3 (23%)	2 (13%)				
Hereditary	0 (0%)	1 (3%)	0 (0%)	6 (46%)	4 (27%)				
Miscellaneous	1 (20%)	0 (0%)	0 (0%)	3 (23%)	3 (20%)				
Current immunosuppression within 3 months <i>n</i> (%)									
Mycophenolate mofetil	0 (0%)	21 (68%)	7 (78%)	1 (8%)	10 (67%)				
Prednisolone	0 (0%)	19 (61%)	4 (45%)	4 (31%)	15 (100%)				
Azathioprine	0 (0%)	1 (3%)	0 (0%)	0 (0%)	2 (13%)				
Cyclosporine A	0 (0%)	1 (3%)	0 (0%)	0 (0%)	1 (7%)				
Tacrolimus	0 (0%)	14 (45%)	6 (67%)	1 (8%)	14 (93%)				
Everolimus	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (27%)				
Hydroxychloroquine	0 (0%)	5 (16%)	1 (11%)	1 (8%)	0 (0%)				
Rituximab	0 (0%)	3 (10%)	3 (33%)	0 (0%)	0 (0%)				
None	5 (100%)	0 (0%)	0 (0%)	9 (69%)	0 (0%)				
Immunosuppression within 1 year n (%)									
Rituximab	0 (0%)	9 (29%)	9 (100%)	0 (0%)	0 (0%)				
Kidney function mean (range)									
eGFR (ml/min/1.73m ²)	38.2 (20-88)	109.7 (25-234)	104.4 (25-234)	NA	62.8 (24-103)				
Urine protein/ creatinine ratio (mg/mmol)	33.2 (1.6-91)	37.2 (6-140)	33.3 (6-108)	NA	26.4 (7-74)				
Kidney failure vintage (year)	0 (0)	0 (0)	0 (0)	3.6 (1-14)	7.4 (3-18)				
Blood count and comorbidities									
Hypertension n (%)	4 (80%)	15 (48%)	4 (44%)	11 (85%)	8 (53%)				
Absolute lymphocyte count (x10 ⁶ /ml) <i>mean (range)</i>	3.9 (1.58-6.47)	2.5 (0.48-5.22)	2.4 (1.08-4.49)	2.1 (0.89-5.18)	2.5 (0.61-5.59)				

It is made available under a CC-BY-NC-ND 4.0 International license .

FIG. S1. IL-2⁺ T cell responses against wild-type SARS-CoV-2 proteins. T cell responses 50 51 against S protein were tested for all participants while responses against S, N and M proteins 52 were only tested for CoronaVac. Geometric means (GM) are shown with center lines and stated 53 above each column. Limits of detection and quantification (LOD and LOQ) and cut-offs were drawn as grey lines. Data points of patients who received intradermal 0.3ml BNT162b2 as dose 54 3 were depicted as rhombi, and those of infected patients were drawn to be hollow beginning 55 56 from after the infection. Data from the same participant were analyzed longitudinally by paired t 57 test after natural logarithmic transformation, and the P values are denoted by asterisks (*, P<0.05; **, P<0.01; ns, not significant). 58



59

It is made available under a CC-BY-NC-ND 4.0 International license .

FIG. S2. Hybrid sVNT and IFN- γ^{+} T cell responses in patients infected prior to

- 61 vaccination. Geometric means (GM) are shown with center lines and stated above each
- 62 column. Geometric means (GM) are shown with center lines and stated above each column.
- Limits of detection and quantification (LOD and LOQ) and cut-offs were drawn as grey lines.
- 64 Data from the same participant were analyzed longitudinally by paired t test after natural
- logarithmic transformation, and the P values are denoted by asterisks (*, P<0.05; **, P<0.01; ns,
- 66 not significant).



